With a market capitalization (market cap) of $3.4B — a measure of how much the company is worth — AbCellera Biologics Inc. is the 1710th most valuable company in Healthcare as of August 18, 2026. Shares trade at $11.12, down +0.71% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Visit websiteAs of August 18, 2026, AbCellera Biologics Inc. (ABCL) is worth $3.4B — this is its market capitalization, the total value of all its outstanding shares.
AbCellera Biologics Inc.’s market cap is $3.4B, which ranks it #1710 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
AbCellera Biologics Inc. (ABCL) shares trade at $11.12, down 0.71% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025